Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912418 · ClinicalTrials.gov registry record · NA
Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma
A NA study of Melanoma, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00912418: Completed NA study of Melanoma, sponsored by Craig L Slingluff, Jr.
NCT00912418 is a NA study of Melanoma that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 14 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00912418, a NA study of Melanoma, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an open-label, pilot study of an autologous tumor cell vaccine.
Conditions Studied
Interventions
- BIOLOGICAL autologous tumor cells plus GM-CSF-in Adjuvant
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2000-05-01 |
| Est. Completion | 2002-10-09 |
| Phase | NA |
What the finished NCT00912418 record still lists
NCT00912418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which autologous tumor cells plus GM-CSF-in Adjuvant is the first listed.
NCT00912418 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT00912418 about?
NCT00912418 is a clinical study titled "Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma". This study is an open-label, pilot study of an autologous tumor cell vaccine.
What is the current status of trial NCT00912418?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2000-05-01. Estimated completion is 2002-10-09.
What conditions does trial NCT00912418 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00912418?
The interventions under investigation include: autologous tumor cells plus GM-CSF-in Adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00912418?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00912418 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00912418's enrollment target sits among peer trials
14 244th of 266 higher than 20 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
RECRUITING · NA
-
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
RECRUITING · NA
-
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy